Clinical Trials

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05015608 2026-05-27

SACHI

Phase 3 Completed

216 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT07079475 2026-05-26

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Phase 1/2 Recruiting

160 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07375316 2026-05-26

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

120 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603791 2026-05-22

Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.

252 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05017025 2026-05-20

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

32 enrolled

Phase 1 Active not recruiting

Lung Neoplasms

NCT04141644 2026-05-19

Osi+Ipi

24 enrolled

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT03191149 2026-05-18

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04181060 2026-05-18

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

300 enrolled

Lung Neoplasms

NCT06417814 2026-05-14

TROPION-Lung15

744 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06486142 2026-05-14

ERIS

200 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02496663 2026-05-13

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

138 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05546866 2026-05-13

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

51 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07376382 2026-05-13

SYNSTAR-02

680 enrolled

GastrointestinalHead & NeckThoracic

NSCLC

NCT05647122 2026-05-11

EGRET

Phase 1 Recruiting

403 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT07329322 2026-05-11

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06670196 2026-05-08

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

420 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05401110 2026-05-07

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06014827 2026-05-07

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

32 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06618287 2026-05-07

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

416 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT05642572 2026-05-06

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06350097 2026-05-06

TROPION-Lung14

582 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-05-05

LAURA

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Lung Neoplasms

NCT04591002 2026-04-30

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

43 enrolled

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT03122717 2026-04-29

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03586453 2026-04-29

Osimertinib In EGFR Mutant Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Completed

423 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02971501 2026-04-28

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

5 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05528458 2026-04-28

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

59 enrolled

Phase 1 Active not recruiting

Adenocarcinoma of Lung

NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Phase NA Active not recruiting

Advanced Non Small Cell Lung Cancer

NCT03969823 2026-04-24

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

148 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03778229 2026-04-23

SAVANNAH

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-04-23

ADAURA2

390 enrolled

674 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT04765059 2026-04-21

COMPEL

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT07535437 2026-04-21

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Phase 1/2 Recruiting

66 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01802632 2026-04-20

AURA

Phase 1/2 Completed

603 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT06838273 2026-04-20

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

720 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07323641 2026-04-20

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03909334 2026-04-17

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

37 enrolled